Information Provided By: 
Fly News Breaks for February 5, 2020
CNC
Feb 5, 2020 | 08:01 EDT
Citi analyst Ralph Giacobbe raised his price target for Centene to $72 from $65 and maintains a Buy rating on the shares post the company's Q4 results. The analyst also introduced a 2022 standalone adjusted earnings per share estimate of $6.00, which assumes 12% earnings growth. He believes the stock deserves a higher multiple given Centene's "strong" competitive positioning within Medicaid, anticipated targeted growth through Medicare Advantage and exchanges, and recently completed WellCare transaction.
News For CNC From the Last 2 Days
CNC
Apr 15, 2024 | 10:37 EDT
Shares of health care facilities and managed care are in the spotlight on Monday after Florida announced late on Friday five winners of six-year Medicaid managed care contracts. Among the winners... To see the rest of the story go to thefly.com. See Story Here
CNC
Apr 15, 2024 | 09:56 EDT
CNC
Apr 15, 2024 | 09:47 EDT
CNC
Apr 15, 2024 | 06:16 EDT
CNC
Apr 15, 2024 | 06:15 EDT
Wells Fargo raised the firm's price target on Centene (CNC) to $93 from $89 and keeps an Overweight rating on the shares. The firm notes Florida intends to award Medicaid contracts to Centene, Elevance Health (ELV), Humana (HUM) and two provider-run plans. Clearly the most positive for Centene given recent disappointing RFP performance and likely most disappointing for Molina Healthcare (MOH) given expectation for share gains, Wells says.
